Drug updated on 12/11/2024
| Dosage Form | Capsule (oral; 150 mg) |
| Drug Class | Hedgehog pathway inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and who are not candidates for radiation.
Latest News
Summary
- This summary is based on the review of four systematic review(s)/meta-analysis(es). [1-4]
- In periocular basal cell carcinoma (BCC), vismodegib achieved a complete clinical response rate between 20-88% and an overall response rate of 68-100%, with disease progression observed at up to 14% and recurrence rates ranging from 0% to 31%. Quality of life improvements were noted.
- For advanced BCC, vismodegib showed a pooled overall response rate (ORR) of 68.5%, compared to 50.1% for sonidegib, indicating higher effectiveness of vismodegib.
- Topical patidegib reduced tumor burden in naive patients with stage II and III BCC but was ineffective in stage IV or previously treated cases, highlighting stage-specific benefits.
- For periocular BCC, common adverse effects of vismodegib include muscle cramps, dysgeusia, weight loss, and alopecia.
- In advanced BCC, vismodegib commonly causes muscle spasms (70.5%), dysgeusia (58.4%), and alopecia (59.9%), with weight loss occurring in 35.1% of cases. Comparatively, sonidegib exhibits slightly lower incidences of these effects but includes higher rates of nausea, diarrhea, increased creatine kinase levels, and decreased appetite.
- Topical patidegib for advanced BCC shows no systemic adverse effects, distinguishing it from systemic Hedgehog pathway inhibitors like vismodegib and sonidegib.
- There is no population type or subgroup information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Erivedge (vismodegib) Prescribing Information. | 2023 | Genentech, Inc., South San Francisco, CA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Super giant basal cell carcinoma: a comprehensive systematic review | 2024 | Annals of Medicine and Surgery |
| Exploring vismodegib: A non-surgical breakthrough in the management of advanced periocular basal cell carcinoma | 2024 | Cancer Treatment and Research Communications |
| Efficacy and Safety of Sonic Hedgehog Inhibitors in Basal Cell Carcinomas: An Updated Systematic Review and Meta-analysis (2009-2022) | 2023 | American Journal of Clinical Dermatology |
| Patidegib in Dermatology: A Current Review | 2021 | International Journal of Molecular Sciences |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Japanese dermatological association guidelines: outlines of Japanese clinical guidelines for basal cell carcinoma 2021. | 2024 | The Journal of Dermatology |
| European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023 | 2023 | European Journal of Cancer |
| Vismodegib for basal cell carcinoma and beyond: What dermatologists need to know. | 2022 | Cutis |
| Guidelines for vismodegib in the management of periocular basal cell carcinoma | 2020 | Canadian Journal of Ophthalmology |